Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19(T2)28z1xx TRAC CAR T Cells in Relapsed or Refractory Large B-Cell Lymphoma
NCT05757700Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2023
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 19(T2)28z1xx TRAC T cell in diffuse large B-cell lymphoma (DLBCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose up to 1 year. Started Feb 2023; status: active, not recruiting.
02
Drugs
19(T2)28z1xx TRAC T cell
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05757700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757700.